GP130 receptor agonist-1 NEW
| Price | $41 | $65 | $128 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-19 |
Product Details
| Product Name: GP130 receptor agonist-1 | CAS No.: 339303-87-6 |
| Purity: 99.62% | Supply Ability: 10g |
| Release date: 2024/11/19 |
Product Introduction
Bioactivity
| Name | GP130 receptor agonist-1 |
| Description | GP130 receptor agonist-1 (N-(4-Fluorophenyl)-4-phenyl-2-thiazolami) is a potent, brain-penetrant and orally active GP130 receptor agonist. |
| In vitro | Compound 2 (N-(4-Fluorophenyl)-4-phenyl-2-thiazolami) treatment showed a 2-fold increase in phosphorylation of STAT3 within 10 min at its regulatory Tyr705 site in SH-SY5Y cells.. Compound 2 treatment increases phosphorylation of AKT at its regulatory Thr308 site and phosphorylation of ERK1/2 at its regulatory Thr202/Tyr204 site in the serum free media condition in SH-SY5Y cells, and in primary cortical neurons. |
| In vivo | For Compound 2 (N-(4-Fluorophenyl)-4-phenyl-2-thiazolami), mice are dosed orally at 10 or 30 mg/kg, or injected subcutaneously (SQ) at 10 mg/kg, and euthanized after 1, 2, 4, 6, and 8 h post dose. At 2 h after SQ delivery at 10 mg/kg the brain Cmax is 161 ng/g while dosing at 30 mg/kg orally, results in the brain Cmax of 156 ng/g (0.57 μM). The brain to plasma ratio for 2 is ～4:1 for oral 30 mg/kg and ～7.5:1 for 10 mg/kg SQ injection. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/ml (203.46 mM) |
| Keywords | neuroprotective | Inhibitor | penetrant | NMDA | inhibit | GP-130 receptor agonist-1 | GP130 receptor agonist-1 | brain | Interleukin Related | GP130 receptor agonist1 | GP130 | GP130 receptor agonist 1 |
| Inhibitors Related | Sodium Thiocyanate | Disulfiram | Deucravacitinib | Apilimod mesylate | Hydrocortisone hemisuccinate | JAK2/STAT3-IN-1 | Y-320 | Balsalazide sodium hydrate | Vidofludimus | Muscone | Apilimod | SC144 |
| Related Compound Libraries | Target-Focused Phenotypic Screening Library | Bioactive Compound Library | Neuroprotective Compound Library | NO PAINS Compound Library | Orally Active Compound Library | Bioactive Compounds Library Max |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $1980.00/50mg |
VIP1Y
|
TargetMol Chemicals Inc.
|
2024-11-19 | |
| $2380.00/50mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-10-23 | |
| $120.00/1KG |
Xiamen Wonderful Bio Technology Co., Ltd.
|
2023-06-28 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY